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Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there
lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was previously used successfully to treat
SARS-CoV-1 and MERS infections. Health authority in Turkey has published a guideline to integrate this promising option in the
treatment process of patients who are prone to high risk of developing severe COVID 19.
Materials and Methods: Forty consecutive patients who had received CP at our center were included in the study. Demographics,
COVID-19 specific parameters, biomarkers to detect the severity of COVID-19 infection and outcome variables were collected
retrospectively. The correlation between outcome variables and the independent predictors of the outcome were reported.
Results: Median age of the patients was 57.5 and 72.5% were male. At least one COVID-19 PCR test was confirmed to be positive in
75% of patients. Remaining 25% had a Chest-CT which was reported to be compatible with an ongoing COVID-19. All patients (100%)
were classified as having severe COVID-19 infection. Over a half of the patients harbored an oxygen saturation of less than 90 despite
of a continuous 5 L/min support of O2. 82.5% of the patients had a need for mechanical ventilation and 45.5% had a need for invasive
mechanical ventilation. Nine out of 10 patients who have received CP outside ICU have totally recovered from COVID-19 at a median
of 9 days, and a half of the patients who needed invasive mechanical ventilation were successfully free of mechanical ventilation support
and managed to recover from COVID-19.
Conclusion: According to the results of this study, CP is an efficient conjunct to conventional therapy against COVID-19 with a
favorable safety profile.
Key words: Convalescent plasma, COVID-19, viral infections

1. Introduction
Since December 2019, a pneumonia associated with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
named as coronavirus disease 2019 (COVID-19) by World
Health Organization (WHO), emerged in Wuhan, China1.
The epidemic spread rapidly worldwide within 3 months
and was characterized as a pandemic by the WHO on
March 11, 2020. To date, there are no proven option for
prophylaxis for those who have been exposed to SARS-

CoV-2, nor therapy for those who develop COVID-19.
Therapeutic strategy for COVID-19 is largely supportive.
Since the effective vaccine and specific antiviral medicines
are unavailable, it is an urgent need to look for an
alternative strategy to treat COVID-19, especially among
severe patients2.
Immune (i.e. “convalescent”) plasma refers to plasma
that is collected from individuals, following resolution of
infection and development of antibodies [1]. There are

World Health Organization (2020). Coronavirus disease (COVID-2019) press briefings [online]. Website https://www.who.int/emergencies/diseases/
novel-coronavirus-2019/media-resources/press-briefings [accessed 11/03/2020].
1

2

Turkish Republic Ministry of Health (2020). COVID-19 Bilgilendirme Sayfası [online]. Website https://covid19.saglik.gov.tr/ [accessed 10/04/2020].
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numerous examples, where CP has been used successfully
as postexposure prophylaxis and/or treatment of infectious
diseases, including other outbreaks of coronaviruses (e.g.,
SARS-CoV-1, Middle East respiratory syndrome [MERS])
[2]. However, the efficacy of CP in critically ill patients
with SARS-CoV-2 infection remains unclear [3–6]. Health
authority in Turkey, has rapidly established a scientific
committee to standardize the treatment of COVID-19.
As novel data emerged showing a potential benefit of
immune plasma therapy, the scientific committee and
health authority has published a guideline to integrate this
promising approach in the treatment process of patients
who are prone to high risk of developing severe COVID-19.
In line with the directives of Ministry of Health, we have
started to use immune plasma therapy institutionally from
7th of April 20202.
Here we share our experience regarding the immune
plasma therapy and aimed to document the efficacy and
safety of this treatment approach.
2. Methods
2.1. Patient selection and ethics
Medipol Hospital Complexes have been converted to
a dedicated pandemic hospital as soon as the first cases
were diagnosed with COVID-19 in Turkey. We have
hospitalized 865 patients as of 28th of April. We have
institutionally followed the guidelines of Ministry of
Health. With the advent of immune plasma specific
guidelines, we have initiated a dedicated service to collect
and provide immune plasma from healthy donors who has
previously recovered from COVID-19. Criteria to detect
eligible patient were as follows:
• To harbor CT signs which can be attributable to a
COVID-19 and at least 50% deterioration of these signs
in 24–48 h,
• A minute respiratory rate over 30,
• A PaO2/FiO2 level of less than 300 mm Hg,
• An oxygen saturation of less than 90% despite of at
least 5 L/min nasal oxygen support,
• A PaO2 of less than 90% despite of at least 5 L/min
nasal oxygen support,
• Need for mechanical ventilation,
• At least two points increase in SOFA score,
• Need for vasopressor support,
• To harbor at least one poor prognostic factor and
patients who are supposed to deteriorate rapidly (severe
lymphopenia, severe CRP, sedimentation rate, ferritin,
LDH, D-dimer elevation).
Approval of an institutional committee consisting of an
infectious disease professional, pulmonology professional
and intensivist were required, and a technical consultation
of hematologist and apheresis unit was made before
selecting the potential patient.
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With regard to the emergent need for any potential
treatment of COVID-19, both Turkish Ministry of Health
and FDA has approved the use of CP against COVID-19
without a need for measuring the neutralizing antibody
titers. That is why we have infused CP products without
obtaining or waiting for the results of neutralizing antibody
titers.
All patients or a first degree relative of the patient
has approved a written informed consent detailing the
procedure and potential side effects.
2.2. Donor selection
Healthy donors were also detected in line with the
directives of health authority.
The criteria to define a potential donor were as follows:
• To have at least one positive laboratory measure
which proves the presence of previous COVID-19.
• If the potential donor was hospitalized with a
diagnosis of COVID-19, at least two consecutive negative
laboratory results indicating the absence or disappearance
and clearance of COVID-19 with a symptom free period
of at least 14 days.
• If the potential donor was not hospitalized, and
followed up at home, with a diagnosis of COVID-19, at
least one negative laboratory results indicating the absence
or disappearance and clearance of COVID-19 with a
symptom free period of at least 28 days.
• To fulfill the conditions of national blood component
donor selection criteria despite of previous viral infection
in last 28 days.
The donors needed to be seronegative for anti-HBV,
HCV and HIV.
200–600 mL CP was collected by apheresis.
2.3. Safety and therapeutic outcome evaluation
We retrospectively collected demographic and clinical
data among patients who had at least one of these
aforementioned criteria and supported with at least one
infusion of immune plasma blood product.
Adverse events and serious adverse events associated
with CP transfusion were assessed by the treating clinician.
The primary outcome was the improvement in
symptoms and chest CT if available in the following days
after indicated intervention. Blood and swab samples were
obtained to measure serum anti-SARS-CoV-2 IgM and IgG
titers and throat SARS-CoV-2 nucleic acid, respectively.
2.4. Statistical analysis
Continous variables were expressed as median (range) and
categorical variables were expressed as number (percent).
Descriptive statistics were used as indicated. Comparisons
between categorical variables were measured using chi‐
square test. Mann–Whitney U test was used to compare
the distribution of continuous variables between 2
independent groups.
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All statistical tests were two sided, and analyses were
performed with SAS 9.4 (SAS Institute Inc., Cary, NC,
USA). A P-value less than 0.05 was accepted as statistically
significant.

All of patients have received additional antiviral
therapy (favipiravir) and 35% of the patients have received
additional anti IL-6 therapy, tocilizumab before the first
CP infusion.

3. Results
Median age of the 40 patients who received at least one
CP infusion was 57.5. Seventy-two and one half percent
of the patients were male and 57.5% of the patients were
grouped as having an “A” blood type. Seventy-five percent
of the patients had a positive COVID-19 PCR test and
the remaining patients harbored typical CT findings
attributable to COVID-19. Median time from the diagnosis
to the infusion of the first CP was 5 days (Table 1). Near all
patients complained of dyspnea, and 77.5% of the patients
had a PaO2/FiO2 level less than 300. Forty-five percent of
the patients needed invasive mechanical ventilation, and
25% required additional vasopressor support.
When compared with patients who have received
the first CP in intensive care unit (ICU), patients who
have received their CP outside the ICU had a favorable
pulmonary profile (Table 2) and they also had a more
favorable biomarker profile (Table 3).
Nine out of the 10 patients who have received the
first infusion outside the ICU have succeeded to recover
from COVID-19 and 1 patient was transferred to ICU
despite having CP infusion and unfortunately lost due to
worsening ARDS. A total of 15 patients who have received
the CP infusion in ICU were succeeded to be free of either
noninvasive (n = 11, 73.3%) or invasive mechanical (n =
4, 26.7%) ventilation and discharged successfully (Figure).
Patients have received a median of 2 (1–3) CP
infusions. Twenty-four (60%) out of the 40 patients have
needed a repeated infusion of the CP at the discretion of
the following physician.

4. Discussion
There exists limited data of the use of CP therapy in viral
infections which can cause ARDS. Previous experience of
this immune therapy has shown promising efficacy with a
favorable safety profile [7–9]. With this regard, as currently
there exists no specific treatment option of COVID 19,
national health authority has accepted CP therapy as a valid
option and developed a national guideline to optimize the
use of aforementioned therapeutic approach.
We tried to document the efficacy and safety of immune
plasma therapy in our 40 consecutive patients treated at our
tertiary center which was a dedicated pandemic hospital.
We have hospitalized 865 patients beginning from 11th of
March to 28th of April. Forty severe COVID-19 patients
have received CP therapy, in both intensive care unit and
nonintensive care wards.
According to the results obtained from our study,
15 patients who received immune plasma therapy have
managed to be free of mechanical ventilation in a median
of 14 days, even they had a prolonged time from initiation
of first symptoms to immune plasma infusion when
compared with the patients who had their infusion in ICU.
This ratio of getting free of invasive mechanical ventilation
was slightly higher than the rates reported in previous
trials [7, 8,10].
All patients who were classified as having severe
COVID 19 and did not transferred to ICU, have managed
to be cured of disease. A half of the patients who were
followed in ICU care have managed to be extubated after
the application of immune plasma therapy.

Table 1. Patient demographics.
All patients

Non-ICU patients
(n = 10)

ICU patients
(n = 30)

P Value

Age

57.5 (35–82)

51 (44–82)

60 (35–73)

0.230

Sex (M/F %)

72.5 / 27.5

66.7 / 33.3

74.2 / 25.8

0.686

A Rh + / A Rh -

19 / 4

2/1

16 / 3

0.096 *

B Rh + / B Rh -

5/2

2/1

3/1

AB Rh + / AB Rh -

3/1

3/0

1/1

0 Rh + / 0 Rh -

5/1

1/1

4/0

COVID 19 PCR positivity - chest CT positivity

75–25

100–0

67.7–33.3

0.081

Interval between diagnosis and first plasma infusion (days)

5 (1–17)

9 (1–16)

4 (2–17)

0.253

Blood typing (n)

* Comparison was made between patients with “A” blood type vs. other blood types among ICU vs. non-ICU groups.
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Table 2. Symptom burden.
All
patients

Non-ICU patients
(n = 10)

ICU patients
(n = 30)

P value

Dyspnea (%)

95

88.9

96.8

0.465

Tachypnea (%)

85

55.6

93.5

0.004

PaO2/FiO2< 300 mmHg (%)

77.5

55.6

83.9

0.012

SaO2< 90 mmHg (despite of a continuous 5 L/min support of O2) (%)

75

66.7

77.4

0.005

PaO2< 70 mmHg (despite of a continuous 5 L/min support of O2) (%)

57.5

33.3

64.5

0.008

Need for mechanical ventilation (%)

82.5

22.2

100

<0.001

Need for invasive mechanical ventilation (%)

45.5

0

48.4

<0.001

Need for vasopressors (%)

25

0

32.3

0.006

Table 3. Presence of poor prognostic biomarkers.
All
patients

Non-ICU
patients

ICU
patients

P value

High ferritin (%)

52.5

33.3

58.1

0.014

High CRP (%)

92.5

100

90.3

0.453

High D-dimer (%)

87.5

55.6

96.8

0.002

Presence of lymphopenia (%)

92.5

88.4

93.5

0.354

Figure. Time to death or discharge from the first infusion of CP.
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None of the patients who were included in the study
has experienced any grade 2 or more toxicity which could
be related to CP infusion. One of the patients had an
episode of fever after the first infusion of CP. No TRALI
(transfusion-related acute lung injury) or severe allergic
reactions were documented. Recently an analysis of 5000
patients who received CP has also confirmed infusion of
CP as a safe therapeutic option [9].
In this current pandemic, there are reports that CP
has been used in China to treat patients with COVID19. In a pilot study of 10 patients with severe COVID-19,
the investigators collected CP with neutralizing antibody
titers at or exceeding a 1:640 dilution [8]. Transfusion of
CP resulted in no serious adverse effect in the recipients.
All 10 patients had improvement in symptoms (e.g., fever,
cough, shortness of breath and chest pain) within 1–3
days of transfusion; they also demonstrated radiological
improvement in pulmonary lesions. In 7 RNA-emic
patients, transfusion of CP was temporally associated
with undetectable viral loads. Further, screening of 39 of
40 (97.5%) of recovered COVID-19 patients displayed
neutralizing antibody titers ≥160. A case series of 5
critically ill patients in China also reported improvement
in clinical status following transfusion with CP (SARSCoV-2 IgG titers >1000) as evidenced by weaning off
mechanical ventilation, reduction in viral loads, improved
oxygenation and clinical stabilization [7].

Our results were also comparable with a recent
publication of Altuntas et.al, in which they have concluded
that, CP therapy seems to be effective for a better course of
COVID-19 in severe and critically ill patients in a Turkish
patient cohort [11].
Retrospective nature of the study and unavailable
neutralizing antibody titers of the donors were the main
limitations of our study. Despite of these limitations
we appreciate the effort of health authority in Turkey to
promote the use of immune plasma treatment even in lack
of currently available antibody titers, as also indicated in
FDA approval of this approach.
One other limitation of this study was its nonrandomized
nature and unstandardized protocol. Unfortunately, as
there exists no specific treatment of COVID-19, near
all patients have received other concomitant therapies,
like; hydroxychloroquine, azithromycin, favipiravir,
tocilizumab, anakinra.
We conclude that immune plasma infusion is an
efficient and safe adjunct treatment in COVID-19. And
best outcome should be achieved when applied prior to
the need for ICU care.
Disclaimer/Conflict of interest
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